Surmontil Related Published Studies
Well-designed clinical trials related to Surmontil (Trimipramine)
Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial. [2009.04]
Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol - A double-blind multicenter trial. [2008.11.25]
Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. [2005.01]
Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. [2003.03]
Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. [2001.03]
Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression. [1996]
Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? [1994]
A comparison of the cardiac safety and therapeutic efficacy of trimipramine versus doxepin in geriatric depressed patients. [1993.08]
[Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure] [1993.03.15]
Effects on sleep: a double-blind study comparing trimipramine to imipramine in depressed insomniac patients. [1989.12]
A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. [1987.12]
Well-designed clinical trials possibly related to Surmontil (Trimipramine)
Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled
randomized trials. [2011]
Receptor occupancy of mirtazapine determined by PET in healthy volunteers. [2007.11]
Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. [2004.10]
Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. [2000.01]
Side effects of adjunct light therapy in patients with major depression. [1997]
Serial partial sleep deprivation as adjuvant treatment of depressive insomnia. [1995.07]
Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment--neurobiological and psychometric assessment of course. [1994.07]
Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment. [1992.03]
Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults. [1990.09]
Factors affecting duodenal ulcer healing. Four double-blind trials in 193 patients. [1982.02.06]
Other research related to Surmontil (Trimipramine)
The effect of trimipramine on dream recall and dream emotions in depressive outpatients. [2009.05.30]
Metabolism in adipose tissue in response to citalopram and trimipramine treatment--an in situ microdialysis study. [2008.06]
[Hypotensive cardio-circulatory failure and metabolic acidosis after suicidal intoxication with trimipramine and quetiapine. Case report and background] [2004.01]
Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. [2003.12]
Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. [2003.10]
Clinical outcome after trimipramine in patients with delusional depression - a pilot study. [2003.01]
Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. [2002.09]
Polysomnographic effects of adjuvant ginkgo biloba therapy in patients with major depression medicated with trimipramine. [2001.03]
Seizures associated with therapeutic doses of venlafaxine and trimipramine. [2000.12]
Fatality caused by a combined trimipramine-citalopram intoxication. [1999.12.06]
Trimipramine fails to exert antimanic efficacy: a case of the discrepancy between in vitro rationale and clinical efficacy. [1999.09]
Effects of the atypical antidepressant trimipramine on field potentials in the low Mg2+-model in guinea pig hippocampal slices. [1998.08]
Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression. [1997.07]
Safety of liver donation after fatal intoxication with the tricyclic antidepressant trimipramine. [1996.11.15]
Trimipramine: a challenge to current concepts on antidepressives. [1996]
Increased trimipramine plasma levels during fluvoxamine comedication. [1994.03]
Chronic effects of trimipramine, an antidepressant, on hippocampal synaptic plasticity. [1993.03]
Antidepressant efficacy and cardiac safety of trimipramine in patients with mild heart disease. [1993.01]
[Suicide with chloroquine combined with maprotiline and trimipramine] [1992.09]
Trimipramine: acute and lasting effects on sleep in healthy and major depressive subjects. [1992.03]
Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects. [1992]
[Eosinophilic pleuritis and hepatopathy under trimipramine therapy] [1991.06.15]
Fatal seizures associated with trimipramine poisoning. [1991.01]
Trimipramine--an atypical neuroleptic? [1991.01]
High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial. [1990.09]
Investigations of morning and laboratory dream recall and content in depressive patients during baseline conditions and under antidepressive treatment with trimipramine. [1990.06]
Effects of scopolamine, trimipramine and diazepam on explicit memory and repetition priming in healthy volunteers. [1990]
[Pulmonary eosinophilic infiltration with pneumothorax during trimipramine treatment] [1989.09.01]
Nonlinear kinetics of trimipramine in depressed patients. [1989.08]
Trimipramine-induced neuroleptic malignant syndrome after transient psychogenic polydipsia in one patient. [1989.04]
Chronopharmacokinetic and bioequivalence studies of two formulations of trimipramine after oral administration in man. [1989.04]
Clinical originality and new biology of trimipramine. [1989]
Trimipramine, anxiety, depression and sleep. [1989]
A review of trimipramine. 30 years of clinical use. [1989]
Depression, circadian rhythms and trimipramine. [1989]
Action of trimipramine on sleep and pituitary hormone secretion. [1989]
Sleep polygraphic effects of trimipramine in depressed patients. Preliminary report. [1989]
The tricyclic trimipramine in the treatment of subjective tinnitus. [1988.03]
Plasma levels and therapeutic response with trimipramine treatment of endogenous depression. [1988.03]
Prevention of recurrent ulcer bleeding, a multicentre study of the effect of ranitidine and trimipramine over one year. [1986]
Other possibly related research studies
[Multiple fibromas in systemic mastocytosis] [2005.05]
Antidepressants and their effect on sleep. [2005.12]
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. [2002.10]
Effects of REM sleep awakenings and related wakening paradigms on the ultradian sleep cycle and the symptoms in depression. [2002.09]
Hydrophobia as a rare presentation of Cotard's syndrome: a case report. [2002.08]
[Delusional depression as differential dementia of the Alzheimer type diagnosis] [2002.05]
Effects of chronic antidepressant treatments on 5-HT and NA transporters in rat brain: an autoradiographic study. [2001.01]
[Tourette's syndrome and antidepressant therapy: exacerbation of nervous tics with paroxetine] [2000.05]
Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. [1998.03]
Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. [1997.05]
[Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis] [1996.05]
[Sleep disorders--what can be done when hypnotics no longer help? Overview and case report] [1995.09]
A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. [1995.08]
Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug resistance. [1995.04.06]
[Psychotropic drug-induced myoclonus] [1995.03]
Antidepressants in suicide: differences in fatality and drug utilisation. [1994]
Post-mortem toxico-kinetics of trazodone. [1992.10]
[Significance of studies of motor activity in depression] [1992.02]
Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. [1991.08]
Pathophysiology of prolonged penile erection associated with trazodone use. [1991.01]
[The anti-koro effect of a tricyclic antidepressant] [1990.05]
[Drugs from the classes of tricyclic antidepressives and antiepileptics, nitrosatable under simulated human gastric conditions] [1989]
Types of interaction of amphiphilic drugs with phospholipid vesicles. [1988.07]
Ghrelin plasma levels during psychopharmacological treatment. [2005]
Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. [2005.04]
Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. [2004]
Risk of fetal exposure to tricyclic antidepressants. [2004.10]
Intrathecal tri-cyclic antidepressants produce spinal anesthesia. [2004.11]
Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. [2004.03]
Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. [2004.03]
Tricyclic antidepressants as long-acting local anesthetics. [2003.05]
Is the nonREM-REM sleep cycle reset by forced awakenings from REM sleep? [2002.11]
Perazine for schizophrenia. [2002]
The use of antidepressant drugs in dermatology. [2001.11]
Adding low-dose antidepressants to interferon alpha treatment for chronic hepatitis C improved psychiatric tolerability in a patient with schizoaffective psychosis. [2000]
Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem. [1999.08]
The utilization of antidepressants--a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994. [1997.08]
Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. [1996.12]
Clinical pharmacokinetics of zopiclone. [1995.12]
Suicide with psychotropic drugs in Switzerland. [1994.05]
|
